Ertugliflozin Pidolate

The dosage of ertugliflozin pidolate must be individualized based on the patient's clinical response and tolerability, as determined by a healthcare provider. According to the standard prescribing information:

• Starting Dose: The recommended starting dose is 5 mg taken orally once daily, typically in the morning.
• Dose Escalation: For patients who require additional glycemic control and who tolerate the 5 mg dose well, the healthcare provider may increase the dose to 15 mg once daily.
• Maximum Dose: The maximum recommended dose is 15 mg per day. Taking more than this amount does not provide additional benefit and significantly increases the risk of side effects.

Before starting treatment, your doctor will likely perform a blood test to check your kidney function (estimated glomerular filtration rate or eGFR) and assess your volume status (hydration level).

As of 2026, the safety and effectiveness of ertugliflozin pidolate in pediatric patients (under the age of 18) have not been established. Therefore, it is not currently approved for use in children. Clinical trials in pediatric populations are often required by the FDA (under the Pediatric Research Equity Act), but until such data are reviewed and approved, this medication should only be used in adults.

Renal Impairment

Because ertugliflozin works by filtering through the kidneys, its efficacy is highly dependent on kidney function.

• eGFR ≥ 45 mL/min/1.73 m²: No dosage adjustment is required.
• eGFR < 45 mL/min/1.73 m²: Initiation of ertugliflozin is not recommended. For patients already taking the drug whose eGFR falls below 45, the healthcare provider will likely discontinue the medication, as its glucose-lowering efficacy decreases while the risk of renal side effects increases.
• eGFR < 30 mL/min/1.73 m²: Use is contraindicated (strictly prohibited) in patients with severe renal impairment, end-stage renal disease (ESRD), or those on dialysis.

Hepatic Impairment

• Mild to Moderate Hepatic Impairment: No dosage adjustment is necessary for patients with Child-Pugh class A or B hepatic impairment.
• Severe Hepatic Impairment: Ertugliflozin has not been studied in patients with severe hepatic impairment (Child-Pugh class C). Therefore, use in this population is not recommended.

Elderly Patients

No specific dosage adjustment is required based solely on age. However, elderly patients (65 years and older) are more likely to have decreased renal function and a higher risk of volume depletion (dehydration) and hypotension (low blood pressure). Healthcare providers should monitor kidney function and hydration status more frequently in this demographic.

• Timing: Take your dose at the same time each day, preferably in the morning. This helps maintain a consistent level of the drug in your system and aligns with the body's natural glucose peaks.
• Administration: Swallow the tablet whole with a glass of water. It can be taken with or without food. Do not crush, chew, or split the tablets unless specifically instructed by your pharmacist, as this may affect how the drug is absorbed.
• Hydration: Because this medication increases glucose and fluid loss through the urine, it is vital to stay adequately hydrated. Drink plenty of non-caffeinated fluids throughout the day unless your doctor has given you a fluid restriction.
• Storage: Keep the medication in its original container at room temperature. Protect it from moisture (avoid storing it in a bathroom cabinet).

If you miss a dose of ertugliflozin pidolate:

1. 1Take it as soon as you remember.
2. 2If it is almost time for your next scheduled dose, skip the missed dose and return to your regular schedule.
3. 3Never take two doses at the same time to make up for a missed one, as this can lead to an increased risk of side effects like dehydration or low blood pressure.

In the event of an overdose, contact your local poison control center or seek emergency medical attention immediately. While specific data on ertugliflozin overdose are limited, symptoms may include severe dehydration, electrolyte imbalances, or significant hypotension. In clinical trials, healthy subjects received single doses up to 100 mg without showing acute toxicity, but individual reactions can vary. Treatment typically involves supportive care, including intravenous hydration and monitoring of vital signs and kidney function.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking this medication without medical guidance, as this could lead to a dangerous spike in blood sugar levels.

Ertugliflozin pidolate is generally well-tolerated, but like all medications, it can cause side effects. The most common side effects are related to the mechanism of increased glucose in the urine, which provides a 'food source' for bacteria and yeast.

• Female Genital Mycotic Infections: Also known as vaginal yeast infections. Symptoms include vaginal itching, soreness, and a thick white discharge. This occurs in approximately 9-12% of female patients.
• Male Genital Mycotic Infections: Yeast infections of the penis (balanitis or balanoposthitis), particularly in uncircumcised men. Symptoms include redness, itching, swelling, or discharge from the penis.
• Urinary Tract Infections (UTIs): Increased frequency of urination, burning sensation during urination (dysuria), or cloudy urine. Serious UTIs, including urosepsis and pyelonephritis (kidney infection), have been reported.
• Increased Urination: Patients may notice they need to urinate more often (polyuria) or more urgently, including during the night (nocturia).

• Thirst and Dehydration: Increased thirst (polydipsia) resulting from the osmotic diuretic effect of the medication.
• Hypotension: A drop in blood pressure, which may cause dizziness or lightheadedness, especially when standing up quickly (orthostatic hypotension).
• Changes in Cholesterol: Some patients may see a slight increase in LDL cholesterol ('bad' cholesterol) levels.
• Weight Loss: While often viewed as a benefit, unintended or rapid weight loss should be monitored.

• Acute Kidney Injury (AKI): Sudden loss of kidney function, often associated with dehydration. Symptoms include decreased urine output or swelling in the legs and feet.
• Hypersensitivity Reactions: Rare cases of serious allergic reactions, including angioedema (swelling of the face/throat) and urticaria (hives).

> Warning: Stop taking Ertugliflozin Pidolate and call your doctor immediately if you experience any of the following serious symptoms:

1. 1Ketoacidosis: This is a life-threatening condition where the body produces high levels of blood acids called ketones. Unlike typical ketoacidosis, SGLT2-induced ketoacidosis can occur even if blood sugar levels are normal (euglycemic ketoacidosis). Symptoms: Nausea, vomiting, abdominal pain, tiredness, and trouble breathing.
2. 2Fournier’s Gangrene: A rare but extremely serious bacterial infection of the skin and tissues under the skin in the genital or anal area (necrotizing fasciitis of the perineum). Symptoms: Pain, tenderness, redness, or swelling in the genital/anal area, along with fever or a general feeling of being unwell.
3. 3Severe Dehydration (Volume Depletion): Excessive loss of body water and salt. Symptoms: Feeling very faint, lightheaded, or dizzy; rapid heartbeat; or dark-colored urine.
4. 4Urosepsis and Pyelonephritis: Severe urinary tract infections that have spread to the blood or kidneys. Symptoms: Fever, back pain, chills, or painful urination.

• Bone Fractures: Some studies of SGLT2 inhibitors have suggested an increased risk of bone fractures. While the VERTIS CV trial did not show a significantly higher risk for ertugliflozin specifically, patients with existing osteoporosis should be monitored closely.
• Lower Limb Amputation: In early trials of other SGLT2 inhibitors (canagliflozin), an increased risk of leg and foot amputations was noted. While subsequent data for ertugliflozin have been more reassuring, patients with a history of prior amputation, peripheral vascular disease, or neuropathy should practice meticulous foot care and report any new sores or infections immediately.
• Renal Function Decline: While SGLT2 inhibitors may provide long-term kidney protection, there can be an initial, transient dip in eGFR when starting the medication. Long-term monitoring is required to ensure kidney health.

As of the most recent FDA updates in 2024, there are no Black Box Warnings for Ertugliflozin Pidolate. However, the drug carries significant 'Warnings and Precautions' regarding ketoacidosis, lower limb amputation risk, and Fournier’s gangrene, which are considered high-priority safety communications.

Report any unusual symptoms or side effects to your healthcare provider. You may also report side effects to the FDA at 1-800-FDA-1088 or via their website.

Ertugliflozin pidolate is a powerful metabolic modifier. Before starting treatment, patients must be aware that this medication changes how the kidneys process sugar and water. This can lead to rapid changes in blood pressure and hydration status. It is essential to maintain a consistent diet and fluid intake. Patients should never stop taking this medication abruptly without consulting their healthcare provider, as this can lead to a rapid increase in blood glucose levels.

No FDA black box warnings are currently issued for Ertugliflozin Pidolate. However, the FDA has issued safety communications for the entire SGLT2 inhibitor class regarding the risk of necrotizing fasciitis of the perineum (Fournier's Gangrene) and the risk of euglycemic ketoacidosis.

Ketoacidosis Risk

Ketoacidosis is a serious, life-threatening condition. Patients taking ertugliflozin should be aware that ketoacidosis can occur even if their blood sugar is not very high (less than 250 mg/dL). Risk factors include a very low carbohydrate diet, acute illness, surgery, or reducing insulin doses too quickly. If you develop nausea, vomiting, or abdominal pain, stop the medication and check for ketones in your urine or blood if possible, then seek immediate medical care.

Lower Limb Amputation

While not as strongly linked to ertugliflozin as it was to canagliflozin, a risk of lower limb amputation (primarily of the toes) exists. Before starting, tell your doctor if you have a history of amputations, heart disease, or circulation problems in your legs. Check your feet daily for redness, sores, or infections.

Volume Depletion and Hypotension

Ertugliflozin causes 'osmotic diuresis,' meaning it pulls water out of the body along with glucose. This can lead to dehydration, especially in patients already taking diuretics (water pills) or those with low blood pressure. Symptoms include dizziness when standing up. Ensure you are drinking enough water, especially in hot weather or during exercise.

Genital Mycotic Infections

Because glucose is present in the urine, yeast can grow more easily. Both men and women are at risk. Practice good hygiene and contact your doctor if you notice itching or discharge.

To ensure the safe use of ertugliflozin, your healthcare provider will require regular monitoring of the following:

• Renal Function (eGFR): Checked before starting and at least annually thereafter. More frequent monitoring is needed if your eGFR is near 45.
• Volume Status: Physical exams to check for signs of dehydration (e.g., skin turgor, blood pressure).
• Blood Glucose and HbA1c: To evaluate the effectiveness of the treatment.
• LDL Cholesterol: Periodic lipid panels may be performed.
• Foot Exams: Regular inspection of the feet for any signs of injury or infection.

Ertugliflozin itself does not usually cause drowsiness. However, if it is used in combination with insulin or a sulfonylurea, it can cause hypoglycemia (low blood sugar), which may impair your ability to drive or operate machinery. Additionally, if you experience dizziness due to low blood pressure, avoid these activities until the symptom resolves.

Alcohol can increase the risk of ketoacidosis and hypoglycemia while taking ertugliflozin. It can also contribute to dehydration. Patients are advised to limit alcohol consumption and discuss their habits with their doctor. Excessive 'binge drinking' is particularly dangerous for patients on SGLT2 inhibitors.

If you are scheduled for surgery, your doctor will likely tell you to stop taking ertugliflozin at least 3 to 4 days before the procedure to reduce the risk of ketoacidosis. Do not restart the medication until you are eating normally and your doctor gives the 'all clear.'

> Important: Discuss all your medical conditions, including any history of pancreas problems, kidney disease, or frequent urinary tract infections, with your healthcare provider before starting Ertugliflozin Pidolate.

There are no absolute drug-drug contraindications where the combination is guaranteed to be fatal; however, ertugliflozin should NEVER be used in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²) or those on dialysis. Combining ertugliflozin with other SGLT2 inhibitors (e.g., Jardiance, Farxiga) is not recommended as it provides no additional benefit and multiplies the risk of side effects.

Insulin and Insulin Secretagogues (e.g., Glipizide, Glyburide)

• Mechanism: While ertugliflozin alone has a low risk of hypoglycemia, adding it to drugs that increase insulin levels can cause blood sugar to drop too low.
• Consequence: Severe hypoglycemia, which can cause confusion, seizures, or loss of consciousness.
• Management: Your doctor may need to lower your dose of insulin or sulfonylurea when you start ertugliflozin.

Diuretics (e.g., Furosemide, Hydrochlorothiazide)

• Mechanism: Both drugs increase urine output and can lead to fluid loss.
• Consequence: Increased risk of severe dehydration, electrolyte imbalance, and acute kidney injury.
• Management: Monitor blood pressure and hydration status closely. Dose adjustments of the diuretic may be necessary.

Lithium

• Mechanism: SGLT2 inhibitors can increase the renal clearance of lithium.
• Consequence: Reduced blood levels of lithium, potentially making it less effective for treating bipolar disorder.
• Management: Monitor serum lithium levels more frequently when starting or stopping ertugliflozin.

UGT Inducers (e.g., Rifampin, Phenytoin)

• Mechanism: These drugs can speed up the metabolism of ertugliflozin via the UGT pathway.
• Consequence: Reduced efficacy of ertugliflozin, leading to higher blood sugar levels.
• Management: Monitor blood glucose levels closely; a dose increase to 15 mg may be required.

• High-Fat Meals: While a high-fat meal slightly delays the time it takes for the drug to reach peak levels, it does not change the overall amount of drug absorbed. Therefore, it can be taken with or without food.
• Caffeine: Excessive caffeine can worsen the diuretic effect (increased urination) and contribute to dehydration.
• Hydration: It is not a drug interaction, but 'interaction' with water is critical. Dehydration significantly increases the risk of renal side effects.

• St. John’s Wort: This herbal supplement is a known inducer of various metabolic enzymes and may potentially reduce the levels of ertugliflozin, though specific studies are lacking.
• Natural Diuretics: Herbs like dandelion, juniper, or parsley may increase the risk of dehydration when combined with ertugliflozin.
• Glucosamine: Some studies suggest glucosamine might interfere with blood sugar control, potentially counteracting the effects of diabetes medications.

• Urine Glucose Test: Because ertugliflozin works by dumping glucose into the urine, a 'dipstick' urine glucose test will always be positive. This is expected and does not indicate a problem.
• 1,5-Anhydroglucitol (1,5-AG) Assay: This specific blood test for glucose control is unreliable in patients taking SGLT2 inhibitors. Use HbA1c or standard blood glucose monitoring instead.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Even 'natural' products can change how your body processes ertugliflozin.

Ertugliflozin pidolate must NEVER be used in the following circumstances:

1. 1Severe Renal Impairment (eGFR < 30 mL/min/1.73 m²): The drug requires functional kidneys to filter glucose. In severe impairment, the drug is ineffective and significantly increases the risk of metabolic complications.
2. 2End-Stage Renal Disease (ESRD) or Dialysis: The mechanism of action is entirely dependent on renal filtration, which is absent or severely compromised in these patients.
3. 3Hypersensitivity: Any patient with a known history of serious allergic reaction (anaphylaxis, angioedema) to ertugliflozin or any of the inactive ingredients in the tablet (such as lactose or magnesium stearate) must not take this medication.

In these situations, a healthcare provider must carefully weigh the risks against the benefits:

• History of Diabetic Ketoacidosis (DKA): Patients prone to ketoacidosis are at much higher risk of developing it again while on an SGLT2 inhibitor.
• Frequent Genital or Urinary Infections: Patients with a history of chronic yeast infections or recurrent UTIs may find these conditions worsen significantly.
• Low Bone Mineral Density: Due to potential (though debated) risks of fractures, patients with severe osteoporosis should be treated with caution.
• Peripheral Vascular Disease: Patients with poor circulation or foot ulcers are at higher risk for complications that could lead to amputation.
• Hypovolemia: Patients who are already dehydrated or have very low blood pressure should have these conditions corrected before starting the drug.

While there is no documented cross-reactivity between SGLT2 inhibitors and other classes of diabetes drugs (like metformin or DPP-4 inhibitors), patients who have had an allergic reaction to other gliflozins (e.g., canagliflozin, dapagliflozin) should be monitored extremely closely, as the chemical structures are related.

> Important: Your healthcare provider will evaluate your complete medical history, including your kidney function and history of infections, before prescribing Ertugliflozin Pidolate.

• Risk Summary: Based on animal data showing adverse renal effects, ertugliflozin pidolate is not recommended during the second and third trimesters of pregnancy.
• Clinical Considerations: Poorly controlled diabetes during pregnancy increases the risk of birth defects, stillbirth, and macrosomia (large baby). However, because the kidneys of the fetus develop during the second and third trimesters, SGLT2 inhibitors could theoretically interfere with this development.
• Recommendation: If you become pregnant, contact your doctor immediately to switch to a safer alternative, such as insulin.

• Passage into Milk: It is not known if ertugliflozin is excreted in human breast milk. However, animal studies have shown the drug is present in the milk of lactating rats.
• Risk to Infant: Because of the potential for serious adverse reactions in the nursing infant—specifically related to kidney development—breastfeeding is not recommended while taking ertugliflozin.

• Age Range: Ertugliflozin is not approved for anyone under the age of 18.
• Safety Concerns: The long-term effects of SGLT2 inhibition on growth and renal development in children are unknown. Type 2 diabetes in children is typically managed with metformin or insulin as first-line therapies.

• Risks: Patients aged 65 and older are at a higher risk for volume depletion (dehydration) and hypotension.
• Renal Function: Since kidney function naturally declines with age, elderly patients are more likely to fall into the eGFR < 45 category where the drug is not recommended.
• Polypharmacy: Older adults are often taking diuretics or blood pressure medications, which increases the risk of drug interactions.

• Dosing: Effectiveness is lost as kidney function declines.
• Monitoring: eGFR must be checked at least once a year. If eGFR falls below 45, the drug should be stopped. It is strictly contraindicated if eGFR is below 30.

• Mild to Moderate: No adjustment needed.
• Severe: Use is not recommended as it has not been studied in this population. The liver plays a role in the glucuronidation of the drug, and severe failure could lead to unpredictable drug levels.

> Important: Special populations require individualized medical assessment. Always inform your doctor if you are planning to become pregnant or are over the age of 65.

Ertugliflozin pidolate is a highly selective inhibitor of the Sodium-Glucose Cotransporter 2 (SGLT2). SGLT2 is the predominant transporter responsible for reabsorbing glucose from the glomerular filtrate back into the blood. By inhibiting SGLT2, ertugliflozin reduces the renal threshold for glucose (RTG) and increases urinary glucose excretion (UGE). In patients with type 2 diabetes, this results in the loss of approximately 70 grams of glucose per day in the urine, which equates to roughly 280 calories. This mechanism is entirely independent of insulin secretion or insulin sensitivity.

• Urinary Glucose Excretion: Following a single oral dose, UGE increases immediately. In healthy volunteers, a 15 mg dose results in significant glucose excretion for 24 hours.
• Blood Pressure: A modest reduction in systolic blood pressure (typically 2-4 mmHg) is observed due to the osmotic diuresis and natriuresis (sodium excretion).
• HbA1c Reduction: Clinical trials show an average HbA1c reduction of 0.7% to 1.0% when used as monotherapy.

| Parameter | Value |

|---|---|

| Bioavailability | ~100% |

| Protein Binding | 93.6% |

| Half-life | ~16.6 hours |

| Tmax | ~1 hour (fasted) |

| Metabolism | UGT1A9 and UGT2B7 (Glucuronidation) |

| Excretion | Renal 50.2%, Fecal 40.9% |

• Molecular Formula: C27H33NO10 (as pidolate salt)
• Molecular Weight: 531.55 g/mol
• Solubility: Soluble in ethanol and acetone; slightly soluble in water.
• Structure: It is a C-glycoside derivative. The pidolate form is the L-pyroglutamic acid salt of ertugliflozin.

Ertugliflozin belongs to the SGLT2 inhibitor class. Other medications in this class include:

• Empagliflozin (Jardiance)
• Dapagliflozin (Farxiga)
• Canagliflozin (Invokana)

Unlike metformin (which works in the liver) or sulfonylureas (which work in the pancreas), SGLT2 inhibitors work exclusively via the kidneys.